Literature DB >> 33582582

Cardiovascular disorders in narcolepsy: Review of associations and determinants.

Poul Jørgen Jennum1, Giuseppe Plazzi2, Alessandro Silvani3, Lee A Surkin4, Yves Dauvilliers5.   

Abstract

Narcolepsy type 1 (NT1) is a lifelong disorder of sleep-wake dysregulation defined by clinical symptoms, neurophysiological findings, and low hypocretin levels. Besides a role in sleep, hypocretins are also involved in regulation of heart rate and blood pressure. This literature review examines data on the autonomic effects of hypocretin deficiency and evidence about how narcolepsy is associated with multiple cardiovascular risk factors and comorbidities, including cardiovascular disease. An important impact in NT1 is lack of nocturnal blood pressure dipping, which has been associated with mortality in the general population. Hypertension is also prevalent in NT1. Furthermore, disrupted nighttime sleep and excessive daytime sleepiness, which are characteristic of narcolepsy, may increase cardiovascular risk. Patients with narcolepsy also often present with other comorbidities (eg, obesity, diabetes, depression, other sleep disorders) that may contribute to increased cardiovascular risk. Management of multimorbidity in patients with narcolepsy should include regular assessment of cardiovascular health (including ambulatory blood pressure monitoring), mitigation of cardiovascular risk factors (eg, cessation of smoking and other lifestyle changes, sleep hygiene, and pharmacotherapy), and prescription of a regimen of narcolepsy medications that balances symptomatic benefits with cardiovascular safety.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Autonomic; Blood pressure; Cardiovascular; Comorbidity; Endothelial; Hypocretin; Mortality; Narcolepsy; Risk factor; Sleep

Year:  2021        PMID: 33582582     DOI: 10.1016/j.smrv.2021.101440

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  8 in total

Review 1.  The translational neuroscience of sleep: A contextual framework.

Authors:  Michael A Grandner; Fabian-Xosé Fernandez
Journal:  Science       Date:  2021-10-28       Impact factor: 47.728

Review 2.  Sleep and Stroke: Opening Our Eyes to Current Knowledge of a Key Relationship.

Authors:  Valerio Brunetti; Eleonora Rollo; Aldobrando Broccolini; Giovanni Frisullo; Irene Scala; Giacomo Della Marca
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-03       Impact factor: 6.030

3.  Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use.

Authors:  Young-A Heo
Journal:  CNS Drugs       Date:  2022-03-31       Impact factor: 6.497

Review 4.  Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy.

Authors:  Yves Dauvilliers; Richard K Bogan; Karel Šonka; Markku Partinen; Nancy Foldvary-Schaefer; Michael J Thorpy
Journal:  Nat Sci Sleep       Date:  2022-03-29

5.  Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.

Authors:  Thomas Roth; Yves Dauvilliers; Michael J Thorpy; Clete Kushida; Bruce C Corser; Richard Bogan; Russell Rosenberg; Jordan Dubow; David Seiden
Journal:  CNS Drugs       Date:  2022-04-05       Impact factor: 5.749

6.  Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort.

Authors:  Carlotta Mutti; Valerio Brunetti; Michela Figorilli; Claudio Liguori; Fabio Pizza; Paola Proserpio; Tommaso Sacco; Giuseppe Pedrazzi; Isabelle Lecomte; Nora Blanchard; Elio Clemente Agostoni; Enrica Bonanni; Diego Centonze; Alessandro Cicolin; Giacomo Della Marca; Luigi Ferini-Strambi; Raffaele Ferri; Gian Luigi Gigli; Francesca Izzi; Rocco Liguori; Raffaele Lodi; Lino Nobili; Liborio Parrino; Fabio Placidi; Monica Puligheddu; Andrea Romigi; Maria Antonietta Savarese; Michele Terzaghi; Giuseppe Plazzi
Journal:  Neurol Sci       Date:  2022-06-25       Impact factor: 3.830

7.  Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.

Authors:  Rebecca Evans; Haruhide Kimura; Robert Alexander; Ceri H Davies; Hélène Faessel; Deborah S Hartman; Takashi Ishikawa; Emiliangelo Ratti; Kohei Shimizu; Motohisa Suzuki; Shinichiro Tanaka; Hiroshi Yukitake; Yves Dauvilliers; Emmanuel Mignot
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

Review 8.  Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity.

Authors:  Maria P Mogavero; Alessandro Silvani; Lourdes M DelRosso; Michele Salemi; Raffaele Ferri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.